SastiMedic
Laviat 10mg Capsule 10s

Laviat 10mg Capsule 10s

MRP: ₹1,220.00

Packaging

CAP

Composition

Lenalidomide 10mg

Company

Zydica Healthcare Ltd

Buy Now

Substitutes for Laviat 10mg Capsule 10s

Medicine Company Price You Save
Lenmid 10 Capsule 10s Cipla ₹998.00 Save ₹222.00
Lenangio 10mg Capsule 10s Dr. Reddy ₹1,013.00 Save ₹207.00
Lenome 10 Capsule 10s Intas ₹1,691.00
Celomide 10mg Capsule 10s Celon Labs ₹1,700.00
Mmlinoda 10mg Capsule 10s Alkem Labs ₹2,169.00
Lenzest 10mg Capsule 10s Sun Pharma ₹2,888.20
Lenid 10mg Capsule 10s United Biotech ₹2,900.00
Mydolen 10 Capsule 10s Miracauls ₹3,000.00
Lendomy 10 Capsule 30s Mylan Pharmaceuticals ₹3,408.00
Lenomust 10 Capsule 30s Panacea Biotec ₹3,465.00
Lenalid 10mg Cap 30s Natco Pharma ₹4,516.18
Kabilen 10mg Capsule 30s Fresenius Kabi ₹4,593.00
Myelomide 10mg Capsule 30s Sun Pharma ₹8,381.00
Nojetor 10mg Capsule 10s Torrent Pharma ₹8,500.00
Giolen 10mg Capsule 30s Innova Life Sciences ₹9,000.00

Side Effects of Laviat 10mg Capsule 10s

HTN, diarrhoea, upper respiratory tract infections, thrombocytopenia, leukopenia, pancytopenia, agranulocytosis, headache, alopecia, dry skin, eczema, erythema multiforme, hypokalaemia, weight loss, asthenia, anxiety, paraesthesia, synovitis, joint disorder, peripheral neuropathy, mild hyperlipidaemia, interstitial lung disease, vasculitis. Potentially Fatal: Hepatotoxicity, sepsis, Stevens-Johnson syndrome, toxic epidermal necrolysis, pancreatitis.

Drug Interactions

Cholestyramine and activated charcoal may decrease plasma concentration of active metabolite. Concurrent use of methotrexate and other hepatotoxic drugs may increase the risk of hepatotoxicity. Rifampicin increases serum levels of the active metabolite. Potentially Fatal: May enhance the adverse effects of live vaccines.

Contraindications

Hepatic impairment, moderate and severe renal impairment, compromised immune function including bone marrow dysplasia or severe uncontrolled infection, severe hypoproteinaemia; concurrent vaccination w/ live vaccines. Pregnancy and lactation.

Mechanism of Action

Leflunomide is an immunomodulating agent and DMARD. It inhibits pyrimidine synthesis by inhibiting dihydroorotate dehydrogenase enzyme activity resulting in antiproliferative and anti-inflammatory effects. Absorption: Bioavailability: Approx 82-95%. Time to peak plasma concentration (active metabolite): 6-12 hr. Distribution: Volume of distribution: 0.13 L/kg. Plasma protein binding (active metabolite): 99% (mainly albumin). Metabolism: Rapidly converted to active metabolite A77 1726 in GI mucosa and the liver. Excretion: Via urine (approx 43% as glucuronides) and faeces (approx 48%). Elimination half-life (active metabolite): Approx 14-18 days.

Special Precautions

Mild renal impairment. Patient w/ history of TB due to the possibility of reactivation of the infection. Monitoring Parameters Monitor BP and liver enzyme values prior to initiation and periodically during therapy.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

  • Alcohol: Avoid during treatment.
  • Breastfeeding: Not recommended.
  • Pregnancy: Contraindicated.
  • Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.

More brands by Zydica Healthcare Ltd

Written by: SastiMedic Medical Team

Reviewed by: Registered Pharmacist